PL209978B1 - Awirulentna postać wirusa DNA karpia powodującego wirusową chorobę ryb, sposób wyodrębniania żywego atenuowanego wirusa DNA karpia, żywy atenuowany wirus karpia otrzymany tym sposobem, sposób diagnozowania choroby związanej z wirusem DNA karpia, szczepionka i zastosowanie szczepionki, oraz zestaw zawierający żywe atenuowane wirusy - Google Patents
Awirulentna postać wirusa DNA karpia powodującego wirusową chorobę ryb, sposób wyodrębniania żywego atenuowanego wirusa DNA karpia, żywy atenuowany wirus karpia otrzymany tym sposobem, sposób diagnozowania choroby związanej z wirusem DNA karpia, szczepionka i zastosowanie szczepionki, oraz zestaw zawierający żywe atenuowane wirusyInfo
- Publication number
- PL209978B1 PL209978B1 PL376441A PL37644103A PL209978B1 PL 209978 B1 PL209978 B1 PL 209978B1 PL 376441 A PL376441 A PL 376441A PL 37644103 A PL37644103 A PL 37644103A PL 209978 B1 PL209978 B1 PL 209978B1
- Authority
- PL
- Poland
- Prior art keywords
- virus
- fish
- dna
- carp
- disease
- Prior art date
Links
- 241000251468 Actinopterygii Species 0.000 title claims abstract description 252
- 230000003053 immunization Effects 0.000 title claims description 30
- 230000009385 viral infection Effects 0.000 title claims description 9
- 208000036142 Viral infection Diseases 0.000 title claims description 5
- 241000700605 Viruses Species 0.000 claims abstract description 376
- 230000002238 attenuated effect Effects 0.000 claims abstract description 86
- 238000000034 method Methods 0.000 claims abstract description 63
- 201000010099 disease Diseases 0.000 claims abstract description 62
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 62
- 108020004414 DNA Proteins 0.000 claims description 130
- 241000252233 Cyprinus carpio Species 0.000 claims description 109
- 101150014408 MINDY3 gene Proteins 0.000 claims description 84
- 101100005010 Mus musculus Ca8 gene Proteins 0.000 claims description 84
- 101150111716 ankrd1 gene Proteins 0.000 claims description 84
- 229960005486 vaccine Drugs 0.000 claims description 62
- 238000002360 preparation method Methods 0.000 claims description 42
- 208000015181 infectious disease Diseases 0.000 claims description 40
- 230000003612 virological effect Effects 0.000 claims description 34
- 210000001519 tissue Anatomy 0.000 claims description 29
- 210000002966 serum Anatomy 0.000 claims description 21
- 238000002649 immunization Methods 0.000 claims description 20
- 238000001493 electron microscopy Methods 0.000 claims description 18
- 210000000056 organ Anatomy 0.000 claims description 18
- 102000053602 DNA Human genes 0.000 claims description 17
- 230000028993 immune response Effects 0.000 claims description 16
- 239000002671 adjuvant Substances 0.000 claims description 15
- 238000009472 formulation Methods 0.000 claims description 15
- 239000000203 mixture Substances 0.000 claims description 15
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 210000000234 capsid Anatomy 0.000 claims description 13
- 238000004113 cell culture Methods 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 238000011282 treatment Methods 0.000 claims description 12
- 241001465754 Metazoa Species 0.000 claims description 11
- 239000007924 injection Substances 0.000 claims description 11
- 238000002347 injection Methods 0.000 claims description 11
- 210000003734 kidney Anatomy 0.000 claims description 11
- 238000012360 testing method Methods 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000001018 virulence Effects 0.000 claims description 10
- 210000004185 liver Anatomy 0.000 claims description 9
- 239000002773 nucleotide Substances 0.000 claims description 9
- 125000003729 nucleotide group Chemical group 0.000 claims description 9
- 210000004369 blood Anatomy 0.000 claims description 8
- 239000008280 blood Substances 0.000 claims description 8
- 208000010824 fish disease Diseases 0.000 claims description 8
- 239000013604 expression vector Substances 0.000 claims description 7
- 230000008569 process Effects 0.000 claims description 7
- 210000002816 gill Anatomy 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000000952 spleen Anatomy 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 4
- 238000007654 immersion Methods 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 210000000936 intestine Anatomy 0.000 claims description 3
- 244000005700 microbiome Species 0.000 claims description 3
- 238000010899 nucleation Methods 0.000 claims description 3
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- LWGJTAZLEJHCPA-UHFFFAOYSA-N n-(2-chloroethyl)-n-nitrosomorpholine-4-carboxamide Chemical compound ClCCN(N=O)C(=O)N1CCOCC1 LWGJTAZLEJHCPA-UHFFFAOYSA-N 0.000 claims 1
- 238000002255 vaccination Methods 0.000 abstract description 5
- 238000002955 isolation Methods 0.000 abstract description 4
- 231100000676 disease causative agent Toxicity 0.000 abstract description 2
- 241000252231 Cyprinus Species 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 30
- 108020005202 Viral DNA Proteins 0.000 description 16
- 239000007787 solid Substances 0.000 description 16
- 241001529453 unidentified herpesvirus Species 0.000 description 15
- 239000000126 substance Substances 0.000 description 14
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 241000283973 Oryctolagus cuniculus Species 0.000 description 12
- 239000012634 fragment Substances 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 8
- 230000000120 cytopathologic effect Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 241000701959 Escherichia virus Lambda Species 0.000 description 7
- 239000000499 gel Substances 0.000 description 7
- 238000011534 incubation Methods 0.000 description 7
- 239000008188 pellet Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000002253 acid Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 238000012258 culturing Methods 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 241001051708 Cyprinid herpesvirus 3 Species 0.000 description 5
- 238000009007 Diagnostic Kit Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 4
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 4
- 108010067770 Endopeptidase K Proteins 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 239000011543 agarose gel Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- 239000012531 culture fluid Substances 0.000 description 4
- 230000005684 electric field Effects 0.000 description 4
- 230000003308 immunostimulating effect Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 241000701161 unidentified adenovirus Species 0.000 description 4
- LHEJDBBHZGISGW-UHFFFAOYSA-N 5-fluoro-3-(3-oxo-1h-2-benzofuran-1-yl)-1h-pyrimidine-2,4-dione Chemical compound O=C1C(F)=CNC(=O)N1C1C2=CC=CC=C2C(=O)O1 LHEJDBBHZGISGW-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 3
- 241000252211 Carassius Species 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000269808 Sparus Species 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000003906 pulsed field gel electrophoresis Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 241000283707 Capra Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000557626 Corvus corax Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000252230 Ctenopharyngodon idella Species 0.000 description 2
- 241000252210 Cyprinidae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000700586 Herpesviridae Species 0.000 description 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 2
- 241000598171 Human adenovirus sp. Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 241000340965 Human papillomavirus type 27 Species 0.000 description 2
- 241000720946 Hypophthalmichthys molitrix Species 0.000 description 2
- 241000252234 Hypophthalmichthys nobilis Species 0.000 description 2
- 241000710921 Infectious pancreatic necrosis virus Species 0.000 description 2
- 241001520921 Leersia virginica Species 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 241000188845 Porcine adenovirus Species 0.000 description 2
- 241000881705 Porcine endogenous retrovirus Species 0.000 description 2
- 108010059712 Pronase Proteins 0.000 description 2
- 208000035415 Reinfection Diseases 0.000 description 2
- 241000701421 Spodoptera exigua multiple nucleopolyhedrovirus Species 0.000 description 2
- 239000005932 Spodoptera exigua nuclear polyhedrosis virus Substances 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003501 co-culture Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002405 diagnostic procedure Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- -1 for example Substances 0.000 description 2
- 239000013505 freshwater Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000002519 immonomodulatory effect Effects 0.000 description 2
- 229960001438 immunostimulant agent Drugs 0.000 description 2
- 239000003022 immunostimulating agent Substances 0.000 description 2
- 230000000366 juvenile effect Effects 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 239000003471 mutagenic agent Substances 0.000 description 2
- 231100000707 mutagenic chemical Toxicity 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 230000007505 plaque formation Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 241000701366 unidentified nuclear polyhedrosis viruses Species 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- VLEIUWBSEKKKFX-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O VLEIUWBSEKKKFX-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108700025333 4'-azido-Phe(6)- herpes simplex virus H2 (6-15) Proteins 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 description 1
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000701412 Baculoviridae Species 0.000 description 1
- 241000537222 Betabaculovirus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 238000011537 Coomassie blue staining Methods 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 241000256054 Culex <genus> Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000199896 Ectocarpus siliculosus Species 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229910052693 Europium Inorganic materials 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 241000701372 Iridovirus Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000721703 Lymantria dispar Species 0.000 description 1
- 208000006758 Marek Disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 206010060860 Neurological symptom Diseases 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 241000700584 Simplexvirus Species 0.000 description 1
- 239000005708 Sodium hypochlorite Substances 0.000 description 1
- 241000519995 Stachys sylvatica Species 0.000 description 1
- 239000008049 TAE buffer Substances 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 239000007984 Tris EDTA buffer Substances 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241001536558 Yaba monkey tumor virus Species 0.000 description 1
- HGEVZDLYZYVYHD-UHFFFAOYSA-N acetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound CC(O)=O.OCC(N)(CO)CO.OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O HGEVZDLYZYVYHD-UHFFFAOYSA-N 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
- 230000006229 amino acid addition Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 229960002756 azacitidine Drugs 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000000249 desinfective effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000001678 irradiating effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018883 loss of balance Diseases 0.000 description 1
- 238000012792 lyophilization process Methods 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000005257 nucleotidylation Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940047091 other immunostimulants in atc Drugs 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000018655 severe necrosis Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical compound [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000000528 statistical test Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/245—Herpetoviridae, e.g. herpes simplex virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/00061—Methods of inactivation or attenuation
- C12N2710/00064—Methods of inactivation or attenuation by serial passage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/01—DNA viruses
- G01N2333/03—Herpetoviridae, e.g. pseudorabies virus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Fodder In General (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Feed For Specific Animals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IL15377503A IL153775A0 (en) | 2003-01-01 | 2003-01-01 | Immunizing fish against viral infection |
| PCT/IL2003/001097 WO2004061093A1 (en) | 2003-01-01 | 2003-12-22 | Immunizing fish against viral infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL376441A1 PL376441A1 (en) | 2005-12-27 |
| PL209978B1 true PL209978B1 (pl) | 2011-11-30 |
Family
ID=29798413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL376441A PL209978B1 (pl) | 2003-01-01 | 2003-12-22 | Awirulentna postać wirusa DNA karpia powodującego wirusową chorobę ryb, sposób wyodrębniania żywego atenuowanego wirusa DNA karpia, żywy atenuowany wirus karpia otrzymany tym sposobem, sposób diagnozowania choroby związanej z wirusem DNA karpia, szczepionka i zastosowanie szczepionki, oraz zestaw zawierający żywe atenuowane wirusy |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US7351527B2 (enExample) |
| EP (1) | EP1578959B1 (enExample) |
| JP (2) | JP4690049B2 (enExample) |
| CN (1) | CN100535108C (enExample) |
| AT (1) | ATE507286T1 (enExample) |
| AU (1) | AU2003288510A1 (enExample) |
| DE (1) | DE60336927D1 (enExample) |
| DK (1) | DK1578959T3 (enExample) |
| IL (2) | IL153775A0 (enExample) |
| PL (1) | PL209978B1 (enExample) |
| RU (1) | RU2369635C2 (enExample) |
| WO (1) | WO2004061093A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5109114B2 (ja) * | 2006-02-24 | 2012-12-26 | 国立大学法人三重大学 | 魚類抗体産生の新規検出法 |
| US8052977B2 (en) * | 2006-04-13 | 2011-11-08 | National University Corporation Tokyo University Of Marine Science And Technology | DNA vaccine for Koi herpes virus (KHV) disease |
| JP5567244B2 (ja) * | 2006-06-06 | 2014-08-06 | 共立製薬株式会社 | 魚類ストレプトコッカス・ディスガラクティエを抗原とする不活化ワクチン |
| RU2010111725A (ru) * | 2007-08-28 | 2011-10-10 | Юниверсите Де Льеж (Be) | Рекомбинантный герпесвирус кои (khv) или герпесвирус 3 семейства карповых (cyhv-3) и вакцина для профилактики заболевания, вызванного khv/cyhv-3 у cyprinus carpio или cyprinus carpio koi |
| EP2031065A1 (en) * | 2007-08-28 | 2009-03-04 | Université de Liège | A recombinant koi herpesvirus (KHV) or Cyprinid herpesvirus 3 (CyHV-3) and a vaccine for the prevention of a disease caused by KHV/CyHV-3 in Cyprinus carpio carpio or Cyprinus carpio koi |
| JP2010143860A (ja) * | 2008-12-19 | 2010-07-01 | Chisso Corp | タンパク質の安定化剤 |
| JP5462518B2 (ja) * | 2009-04-09 | 2014-04-02 | 公益財団法人ヒューマンサイエンス振興財団 | 抗体精製方法 |
| EP2487241A1 (en) | 2011-02-09 | 2012-08-15 | Westfälische Wilhelms-Universität Münster | RNAi agents and compositions useful as carp therapeutics |
| UA119786C2 (uk) | 2011-12-30 | 2019-08-12 | Гесваль С.А. | Рекомбінантний герпесвірус кої (khv) і вакцина для профілактики захворювання, що викликається khv |
| DK2969966T3 (en) * | 2013-03-15 | 2018-08-13 | Atlantium Tech Ltd | SYSTEM AND PROCEDURE FOR INACTIVATING INFECTIOUS PANCREAS CROSSVIRUS (IPNV) USING OPTIMIZED ULTRAVIOLET (UV) LIGHT |
| JP6406703B2 (ja) * | 2013-05-15 | 2018-10-17 | 国立研究開発法人水産研究・教育機構 | コイ科ヘルペスウイルス−２（Ｃｙｐｒｉｎｉｄｈｅｒｐｅｓｖｉｒｕｓ−２：ＣｙＨＶ−２）感染症用ワクチンおよびその製造方法、ならびにＣｙＨＶ−２ウイルス製造方法 |
| CN103430936A (zh) * | 2013-09-06 | 2013-12-11 | 中国水产科学研究院黑龙江水产研究所 | 一种用于鱼类基因组dna提取的鱼鳍组织的制备方法 |
| IL230970A0 (en) * | 2014-02-13 | 2014-09-30 | Univ Ramot | Tilapia virus vaccines |
| CN104774802B (zh) * | 2015-04-27 | 2017-12-08 | 上海海洋大学 | 银鲫鱼背鳍细胞系 |
| RU2640346C1 (ru) * | 2016-08-11 | 2017-12-27 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Государственный аграрный университет Северного Зауралья" (ФГБОУ ВО ГАУ Северного Зауралья) | Способ антиоксидантной защиты мальков карпа |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5780448A (en) * | 1995-11-07 | 1998-07-14 | Ottawa Civic Hospital Loeb Research | DNA-based vaccination of fish |
-
2003
- 2003-01-01 IL IL15377503A patent/IL153775A0/xx unknown
- 2003-12-22 AU AU2003288510A patent/AU2003288510A1/en not_active Abandoned
- 2003-12-22 CN CNB2003801080535A patent/CN100535108C/zh not_active Expired - Lifetime
- 2003-12-22 PL PL376441A patent/PL209978B1/pl unknown
- 2003-12-22 RU RU2005120158A patent/RU2369635C2/ru not_active IP Right Cessation
- 2003-12-22 EP EP03780585A patent/EP1578959B1/en not_active Expired - Lifetime
- 2003-12-22 AT AT03780585T patent/ATE507286T1/de not_active IP Right Cessation
- 2003-12-22 WO PCT/IL2003/001097 patent/WO2004061093A1/en not_active Ceased
- 2003-12-22 DE DE60336927T patent/DE60336927D1/de not_active Expired - Lifetime
- 2003-12-22 DK DK03780585T patent/DK1578959T3/da active
- 2003-12-22 JP JP2004564397A patent/JP4690049B2/ja not_active Expired - Fee Related
-
2005
- 2005-06-27 IL IL169412A patent/IL169412A/en active IP Right Grant
- 2005-06-30 US US11/170,793 patent/US7351527B2/en not_active Expired - Lifetime
-
2010
- 2010-08-20 JP JP2010185273A patent/JP2011024584A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| RU2369635C2 (ru) | 2009-10-10 |
| ATE507286T1 (de) | 2011-05-15 |
| AU2003288510A1 (en) | 2004-07-29 |
| IL169412A (en) | 2011-04-28 |
| DK1578959T3 (da) | 2011-08-15 |
| EP1578959B1 (en) | 2011-04-27 |
| AU2003288510A8 (en) | 2004-07-29 |
| CN1742083A (zh) | 2006-03-01 |
| PL376441A1 (en) | 2005-12-27 |
| EP1578959A1 (en) | 2005-09-28 |
| JP2011024584A (ja) | 2011-02-10 |
| US7351527B2 (en) | 2008-04-01 |
| WO2004061093A1 (en) | 2004-07-22 |
| CN100535108C (zh) | 2009-09-02 |
| IL153775A0 (en) | 2003-07-31 |
| JP2006512078A (ja) | 2006-04-13 |
| US20060013828A1 (en) | 2006-01-19 |
| DE60336927D1 (enExample) | 2011-06-09 |
| JP4690049B2 (ja) | 2011-06-01 |
| RU2005120158A (ru) | 2006-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011024584A (ja) | ウイルス感染に対する免疫魚 | |
| KR101732240B1 (ko) | Ｉｂ ｑｘ-유사 균주로부터 유래된 감염성 기관지염 백신 | |
| US8178110B2 (en) | Reovirus compositions and methods of use | |
| CN107287218A (zh) | 鸡传染性支气管炎强毒株s1基因及其强毒株和应用 | |
| CN101596312A (zh) | 孢子纲物种体外培养的方法及其用途 | |
| Bosco-Lauth et al. | A novel vaccine candidate against rabbit hemorrhagic disease virus 2 (RHDV2) confers protection in domestic rabbits | |
| AU2002253542B2 (en) | Purified subfragment encoding neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis | |
| CN118480515B (zh) | 一种猪繁殖与呼吸综合征病毒nadc30病毒株及其应用 | |
| KR102769557B1 (ko) | 신규한 재조합 돼지 써코바이러스 2형 단백질 및 이의 용도 | |
| CN100384988C (zh) | 2型鸡星状病毒 | |
| KR101085667B1 (ko) | 오리 질병에 대한 면역항체가 함유된 난황분말의 생산방법 및 이에 따른 난황분말 | |
| Kurukulasuriya | Efficacy of vaccines against variant infectious bursal disease viruses to control immunosuppression in the broiler chicken industry in Canada | |
| KR100468037B1 (ko) | 신규한 닭 전염성 기관지염 바이러스(ｉｂｖ) 및 이를이용한 닭 전염성 기관지염 (ｉｂ) 감염 예방백신 | |
| Harkinezhad et al. | Protection of budgerigars (Melopsittacus undulatus) against Chlamydophila psittaci challenge by DNA vaccination | |
| CN118931848B (zh) | 一种猪圆环病毒3型病毒株及其应用 | |
| KR100391265B1 (ko) | 흑염소 로타 바이러스 순화주, 이의 제조 방법 및 용도 | |
| Atkinson et al. | Efficacy of a commercial cararypox vaccine for protecting HawaiiAmakihi from field isolates of avipoxvirus. | |
| KWONG | Vaccination Efficacies against Myxomatosis | |
| Abd El-Ghany | Forms of avian reovirus in poultry production: An overview | |
| CN112773892A (zh) | 一种猪伪狂犬病毒弱毒株冻干疫苗 | |
| Abbassi et al. | The following abstracts are from the oral and poster sessions presented at the Poultry Medicine Section of the 1999 AVMA Annual Convention in New Orleans, La, July 10-July 14, 1999. Abstracts for the Poultry Medicine Section | |
| Srivastava et al. | NEPHROTIC SYNDROME IN A SIAMESE CAT | |
| Ilouze et al. | Characterization of a Novel Virus Causing | |
| CN113249341A (zh) | 一种猪伪狂犬病毒双基因缺失株 | |
| Müller | Virus-Host Adatation and Co-Evolution of Myxoma Virus (Mv) and Rabbit Haemorrhagic Disease Virus (Rhdv) in Their Natural Host, the Wild Rabbit (Oryctolagus Cuniculus) |